Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase-2 Superiority Trial
Jan J. Sprengers, Dorinde M. van Andel, Nicolaas P. A. Zuithoff, et al.
Journal of the American Academy of Child & Adolescent Psychiatry (2020) Vol. 60, Iss. 7, pp. 865-876
Open Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

An Update on Psychopharmacological Treatment of Autism Spectrum Disorder
Ramkumar Aishworiya, Tatiana Valica, Randi J. Hagerman, et al.
Neurotherapeutics (2022) Vol. 19, Iss. 1, pp. 248-262
Open Access | Times Cited: 146
The role of GABAergic signalling in neurodevelopmental disorders
Xin Tang, Rudolf Jaenisch, Mriganka Sur
Nature reviews. Neuroscience (2021) Vol. 22, Iss. 5, pp. 290-307
Open Access | Times Cited: 135
Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications
Chen-Chen Jiang, Lishan Lin, Sen Long, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 130
PTEN mutations impair CSF dynamics and cortical networks by dysregulating periventricular neural progenitors
Tyrone DeSpenza, Emre Kiziltug, Garrett Allington, et al.
Nature Neuroscience (2025)
Closed Access | Times Cited: 2
Repetitive Restricted Behaviors in Autism Spectrum Disorder: From Mechanism to Development of Therapeutics
Junbin Tian, Xuping Gao, Li Yang
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 60
CNS pharmacology of NKCC1 inhibitors
Wolfgang Löscher, Kai Kaila
Neuropharmacology (2021) Vol. 205, pp. 108910-108910
Open Access | Times Cited: 59
Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response
Gonzalo Salazar de Pablo, Carolina Pastor Jordá, Julio Vaquerizo‐Serrano, et al.
Journal of the American Academy of Child & Adolescent Psychiatry (2022) Vol. 62, Iss. 2, pp. 151-168
Open Access | Times Cited: 50
Dysregulation of GABAergic Signaling in Neurodevelomental Disorders: Targeting Cation-Chloride Co-transporters to Re-establish a Proper E/I Balance
Enrico Cherubini, Graziella Di Cristo, Massimo Avoli
Frontiers in Cellular Neuroscience (2022) Vol. 15
Open Access | Times Cited: 41
Novel treatments in autism spectrum disorder
Danielle Baribeau, Jacob Vorstman, Evdokia Anagnostou
Current Opinion in Psychiatry (2022) Vol. 35, Iss. 2, pp. 101-110
Closed Access | Times Cited: 38
Pharmacological tools to target NKCC1 in brain disorders
Annalisa Savardi, Marco Borgogno, Marco De Vivo, et al.
Trends in Pharmacological Sciences (2021) Vol. 42, Iss. 12, pp. 1009-1034
Open Access | Times Cited: 50
Chloride transporters controlling neuronal excitability
Jessica C. Pressey, Miranda de Saint-Rome, Vineeth A. Raveendran, et al.
Physiological Reviews (2022) Vol. 103, Iss. 2, pp. 1095-1135
Closed Access | Times Cited: 38
Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD)
Michelle Iffland, Nuala Livingstone, Mikaela Jorgensen, et al.
Cochrane library (2023) Vol. 2023, Iss. 10
Closed Access | Times Cited: 20
Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies
Joaquín Fuentes, Mara Parellada, Christina Georgoula, et al.
Autism Research (2023) Vol. 16, Iss. 10, pp. 2021-2034
Open Access | Times Cited: 19
Probiotics and Prebiotics in the Treatment of Autism Spectrum Disorder: A Narrative Review
Si Zhang, Fei Han, Qiong Wang, et al.
Journal of Integrative Neuroscience (2024) Vol. 23, Iss. 1, pp. 20-20
Open Access | Times Cited: 8
The domestic chick as an animal model of autism spectrum disorder: building adaptive social perceptions through prenatally formed predispositions
Toshiya Matsushima, Takeshi Izumi, Giorgio Vallortígara
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 7
Novel treatments for autism spectrum disorder based on genomics and systems biology
Danielle Baribeau, Evdokia Anagnostou
Pharmacology & Therapeutics (2021) Vol. 230, pp. 107939-107939
Open Access | Times Cited: 35
Prediction of Behavioral Improvement Through Resting-State Electroencephalography and Clinical Severity in a Randomized Controlled Trial Testing Bumetanide in Autism Spectrum Disorder
Erika L. Juárez-Martinez, Jan J. Sprengers, Gianina Cristian, et al.
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2021) Vol. 8, Iss. 3, pp. 251-261
Open Access | Times Cited: 35
Systematic Review and Meta-analysis: Pharmacological and Nonpharmacological Interventions for Persistent Nonepisodic Irritability
Rosanna Breaux, Raman Baweja, Hana‐May Eadeh, et al.
Journal of the American Academy of Child & Adolescent Psychiatry (2022) Vol. 62, Iss. 3, pp. 318-334
Closed Access | Times Cited: 25
Antihypertensive drugs and brain function: mechanisms underlying therapeutically beneficial and harmful neuropsychiatric effects
Carla Carnovale, Cristiana Perrotta, Sara Baldelli, et al.
Cardiovascular Research (2022) Vol. 119, Iss. 3, pp. 647-667
Open Access | Times Cited: 25
Sustainable production of active pharmaceutical ingredients from lignin-based benzoic acid derivatives via “demand orientation”
Yuguo Dong, Lin Dong, Xiaoli Gu, et al.
Green Chemistry (2023) Vol. 25, Iss. 10, pp. 3791-3815
Closed Access | Times Cited: 14
The GABA Polarity Shift and Bumetanide Treatment: Making Sense Requires Unbiased and Undogmatic Analysis
Yehezkel Ben‐Ari, Enrico Cherubini
Cells (2022) Vol. 11, Iss. 3, pp. 396-396
Open Access | Times Cited: 21
Effects of Bumetanide on Neurocognitive Functioning in Children with Autism Spectrum Disorder: Secondary Analysis of a Randomized Placebo-Controlled Trial
Dorinde M. van Andel, Jan J. Sprengers, Marsh Königs, et al.
Journal of Autism and Developmental Disorders (2023) Vol. 54, Iss. 3, pp. 894-904
Open Access | Times Cited: 12
Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease
Ben Boyarko, Sonia Podvin, Barry Greenberg, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 12
The role of SLC12A family of cation-chloride cotransporters and drug discovery methodologies
Shiyao Zhang, Nur Farah Meor Azlan, Sunday Solomon Josiah, et al.
Journal of Pharmaceutical Analysis (2023) Vol. 13, Iss. 12, pp. 1471-1495
Open Access | Times Cited: 11
Protective effects of rosmarinic acid against autistic-like behaviors in a mouse model of maternal separation stress: behavioral and molecular amendments
Maziar Mahmoudian, Zahra Lorigooini, Mohammad Rahimi-Madiseh, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 10, pp. 7819-7828
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top